Start-up Nuron gains preclinical amyloid beta 42 DNA vaccine for Alzheimer's
This article was originally published in Scrip
Executive Summary
Nuron Biotech, a two-year old privately held US biologics and vaccines company, has brought in another licensing deal. It has licensed from Vitruvian BioMedical a gene-based amyloid 42 (Abeta42) vaccine that is in preclinical development for Alzheimer's disease. Nuron obtained an exclusive, worldwide licence for the vaccine and is responsible for the development and commercialisation.